Search the Newsreel

Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates

FY2026 EPS Estimates for Compugen Raised by HC Wainwright

Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ...

Compugen Ltd (CGEN) reported Q2 2026 earnings, detailing a cash position of $125.3 million expected to fund operations into 2029. The company is advancing its COM701 program with the MyOvarian trial, targeting an interim analysis by Q1 2027, and continues to benefit from AstraZeneca's …

Compugen Ltd. (NASDAQ:CGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Compugen Ltd. (NASDAQ:CGEN) has received a consensus "Moderate Buy" rating from five brokerages, with an average 12-month price target of $5.00, significantly above its recent share price of $2.38. The biotechnology company recently surpassed analyst expectations for its quarterly results, reporting a smaller loss …

Compugen (CGEN) Stock Holds Steady As Cash Runway Extends To 2029

Compugen's stock remained stable after its Q2 2026 earnings, which showed a small increase in revenue to US$2.6m and a net loss of US$7m, with a cash runway extending to 2029. The company's bullish case relies on clinical milestones, particularly the MAIA ovarian trial …

Compugen Ltd expected to post a loss of 8 cents a share - Earnings Preview

Compugen Ltd is projected to report a loss of 8 cents per share in its upcoming earnings announcement. This preview indicates the financial expectations for the company's performance.

Compugen stock maintained at Buy by H.C. Wainwright on trial data

H.C. Wainwright reiterated a Buy rating and a $4.00 price target for Compugen (NASDAQ:CGEN) after the company revised assumptions for its MAIA-ovarian study. Compugen adjusted its estimated median progression-free survival for the placebo arm to four months, down from 5.5 months, aligning with findings …

Compugen Sets September 10, 2026 Annual Meeting, Details Board, Pay and Auditor Votes

Press Release: Compugen Reports Second Quarter 2026 Results

This press release from Compugen reports their financial and operational results for the second quarter of 2026. It will likely detail key achievements, financial performance metrics, and potentially updates on their drug development pipeline.

Compugen Releases Q2 2026 Financial Results

Compugen Ltd. reported its Q2 2026 financial results, showcasing a narrower loss of $0.07 per share, beating analyst expectations, and a significant revenue increase of 107.0% to $2.6M. The clinical-stage therapeutic discovery company recorded a net loss of $7.0M as it continues to advance …

Compugen (NASDAQ: CGEN) seeks votes on directors, pay policy and auditor

Compugen Ltd. (NASDAQ: CGEN) has announced its 2026 annual shareholder meeting for September 10, 2026, where shareholders will vote on key corporate governance issues. These include the election of eight directors, the approval of an amended compensation policy for executives and directors, and the …

Compugen posts investor presentation on immuno-oncology antibody pipeline, partnerships and cash runway

Compugen has released an investor presentation detailing its immuno-oncology antibody pipeline, partnerships, and financial outlook. The company reported a cash balance of $125.3 million as of June 30, 2026, expecting it to last into 2029. Key pipeline updates include progress on COM701 for ovarian …

Compugen's ovarian cancer trial on track with key data due Q1 2027; strong financials support pipeline through 2029

Compugen Ltd. announced significant progress in its MAIA-ovarian trial for platinum-sensitive ovarian cancer, with key progression-free survival data expected in Q1 2027. The company also highlighted advancements in collaborations with AstraZeneca and Gilead and reported a strong financial position with $125.3 million in cash, …

Compugen (NASDAQ: CGEN) reports H1 2026 results, cash runway into 2029

Compugen (NASDAQ: CGEN) reported its H1 2026 results, showing $4.8 million in revenue and a net loss of $14.7 million. Despite the loss, the company maintains a strong financial position with approximately $125.3 million in cash, cash equivalents, short-term bank deposits, and marketable securities, …

Compugen: Cash Runway Expected to Fund Ops Into 2029 >CGEN.TV

Compugen announced that its current cash reserves are projected to fund operations well into 2029. This extended cash runway provides the company with significant financial stability and flexibility for its ongoing research and development efforts.

Compugen (NASDAQ:CGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Compugen Ltd. announced its financial results for the second quarter and six months ended June 30, 2026. For Q2 2026, the company reported sales of USD 2.6 million, an increase from USD 1.26 million in the prior year, with a net loss of USD …

Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates

Compugen earnings beat, revenue topped estimates

Earnings To Watch: Compugen Ltd (CGEN) Reports Q2 2026 Result

CGEN Q2'26 Earnings: EPS estimate is (0.08) USD

Compugen (CGEN) grants director options and RSUs with long vesting

Compugen director Eran Perry received two equity awards on July 29, 2026: 10,000 share options at an exercise price of $2.26 and 7,500 restricted stock units (RSUs). Both awards have a long vesting schedule, with 25% vesting on October 1, 2027, and the remainder …

Compugen (CGEN) awards 100,000 share options to director Anat Cohen-Dayag

Compugen Ltd. (CGEN) has awarded 100,000 share options to director Anat Cohen-Dayag, allowing her to purchase Ordinary Shares at an exercise price of $2.2600 per share. These options, which expire on July 29, 2036, will vest 25% on September 30, 2027, with the remainder …

Compugen (CGEN) grants CFO 26,000 options and 19,500 RSUs

Compugen Ltd. (CGEN) has granted its Chief Financial Officer, David Silberman, 19,500 restricted stock units (RSUs) and 26,000 share options, with an exercise price of $2.26 and an expiration date of July 29, 2036. Both awards will vest 25% on September 30, 2027, with …

Compugen (CGEN) awards CEO Ophir Eran 200,000 share options

Compugen Ltd. (CGEN) CEO Ophir Eran was granted 200,000 share options for ordinary shares on July 29, 2026. These options have an exercise price of $2.2600 and are set to expire on July 29, 2036. The options will vest 25% on September 30, 2027, …

Form 4 COMPUGEN LTD For: 30 July By Investing.com

This article reports on a Form 4 filing for COMPUGEN LTD on July 30, 2026. Form 4 filings are legally required documents filed with the SEC whenever there is a material change in the holdings of company insiders. The article provides a brief overview …

Compugen (CGEN) awards options and RSUs to board director

Compugen Ltd. (CGEN) director Mathias Hukkelhoven was granted equity awards on July 29, 2026. The awards include options for 10,000 Ordinary Shares with a $2.26 exercise price and an RSU award for 7,500 shares. Both awards are subject to vesting schedules tied to his …

COMPUGEN LTD (CGEN) grants 24,000 share options and 18,000 RSUs to SVP

COMPUGEN LTD (CGEN) has granted SVP of Business Development, Zurit Levine, 18,000 restricted stock units (RSUs) and 24,000 share options with an exercise price of $2.26 per share. Both awards have an initial vesting of 25% on September 30, 2027, with the remainder vesting …

Compugen Ltd (CGEN) grants RSUs and stock options to senior executive

Compugen Ltd (CGEN) has awarded SVP of Research & Discovery, Kredo Russo Sharon, with 18,000 restricted stock units and options for 24,000 ordinary shares at an exercise price of $2.26. Both awards were granted on July 29, 2026, and are subject to a vesting …

Compugen Ltd (CGEN) awards COO Pierre Ferre 70,000 stock options

Compugen Ltd (CGEN) has awarded its Chief Operating Officer, Pierre Ferre, 70,000 share options at an exercise price of $4.00 per share. These options are set to expire on July 29, 2036, with a vesting schedule that grants 25% on September 30, 2027, and …

Compugen Ltd (CGEN) Institutional Confidence

Compugen Ltd (CGEN) has an institutional shareholding score of 3.00, ranking it 191 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion stands at 14.54%, showing a 16.20% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding …

Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis

Compugen Ltd (CGEN) has a financial score of 6.25, ranking 274 out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company reported a quarterly revenue of $2.18M, with year-over-year decreases of 4.73% in revenue …

Compugen Ltd. Revenue Breakdown – NASDAQ:CGEN